四条通道加快好药新药上市

Core Viewpoint - The newly revised "Regulations for the Implementation of the Drug Administration Law of the People's Republic of China" will take effect on May 15, marking the first comprehensive revision in 23 years, with over 90% of the clauses modified from the previous version [1] Group 1: Encouragement of Drug Innovation - A significant feature of the revision is the encouragement of drug research and innovation, emphasizing the creation of new drugs guided by clinical value and improving the quality and efficacy of generic drugs [1][3] - The regulations establish a fast-track review process for drug approvals, including breakthrough therapies and conditional approvals, to expedite the market entry of new and effective drugs [1][2] Group 2: Protection of Drug Intellectual Property - The revision strengthens the protection of drug intellectual property, encouraging continuous research and innovation by enterprises [3] - It introduces a market exclusivity period for pediatric and rare disease drugs, with up to 2 years for pediatric drugs and up to 7 years for rare disease drugs, aligning with international practices [4] - The data protection period allows innovative drug companies to achieve reasonable returns, supporting ongoing research and innovation, while enabling generic drug companies to simplify their market entry after this period [4]